Janney Montgomery Scott Starts GW Pharma (GWPH) at Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St set to fall at open as yields and oil rebound; Fed minutes in focus
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
GW Pharma's (GWPH) Price Target Raised to $152 at Morgan Stanley
June 28, 2016 7:58 AM EDTMorgan Stanley maintained an Overweight rating on GW Pharma (NASDAQ: GWPH) and raised its price target to $152.00 (from $149.00).
For an analyst ratings summary and ratings history on GW Pharma click here. For more ratings news on GW Pharma click here.
Shares of GW Pharma closed at $88.49 yesterday.
... More


